Recently added

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

Llorente, Sofía; Lamarca, Angela; TIAN, TIAN (Springer Nature, 2025-06-27)

EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update

Rüegg, Linda; Pluma Sanjurjo, Andrea; HAMROUN, SABRINA; Cecchi, Irene; Perez, Luis ; Anderson, Philip (Elsevier, 2025-06)

Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data

Cervera, Ricard; Freire-González, Mercedes; Turrión Nieves, Ana Isabel; Rua Figueroa, Iñigo; Cortes Hernandez, Josefina; Castellvi, Ivan (BMJ, 2025-07-22)

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer

Li, Michelle; Barberi, Vittoria; Salgado, Roberto; Panet, François; Oliveira, Mafalda; Loi, Sherene (Elsevier, 2025-10)

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Preusser, Matthias; Garde-Noguera, Javier; GARCIA MOSQUERA, JUAN JOSE; Gion, María; Greil, Richard; Arumí De Dios, Míriam (Nature Portfolio, 2025-08)

Scientia. Department of Health Digital Information Depot

Institut Català de la Salut - ICS: Recent submissions

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update

Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Scientia. Department of Health Digital Information Depot

Institut Català de la Salut - ICS: Recent submissions

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors ﻿

EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update ﻿

Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data ﻿

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer ﻿

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial ﻿

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update

Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data

Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial